WO1999057253A3 - Crystallizable jnk complexes - Google Patents

Crystallizable jnk complexes Download PDF

Info

Publication number
WO1999057253A3
WO1999057253A3 PCT/US1999/009824 US9909824W WO9957253A3 WO 1999057253 A3 WO1999057253 A3 WO 1999057253A3 US 9909824 W US9909824 W US 9909824W WO 9957253 A3 WO9957253 A3 WO 9957253A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
complexes
jnk3
molecules
active site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/009824
Other languages
French (fr)
Other versions
WO1999057253A2 (en
Inventor
Xiaoling Xie
Yong Gu
William Markland
Michael S Su
Paul R Caron
Edward Fox
Keith P Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to JP2000547209A priority Critical patent/JP2002513562A/en
Priority to AU37868/99A priority patent/AU3786899A/en
Priority to EP99920350A priority patent/EP1076692A2/en
Publication of WO1999057253A2 publication Critical patent/WO1999057253A2/en
Publication of WO1999057253A3 publication Critical patent/WO1999057253A3/en
Priority to US09/706,128 priority patent/US7383135B1/en
Anticipated expiration legal-status Critical
Priority to US12/150,328 priority patent/US8002891B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to a data storage medium encoded with the corresponding structure coordinates of molecules and molecular complexes which comprise the active site binding pockets of JNK3. A computer comprising such data storage material is capable of displaying such molecules and molecular complexes, or their structural homologues, as a graphical three-dimensional representation on a computer screen. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen and design compounds, including inhibitory compounds, that bind to JNK3 or homologues thereof. This invention also relates to molecules and molecular complexes which comprise the active site binding pockets of JNK3 or close structural homologues of the active site binding pockets.
PCT/US1999/009824 1998-05-04 1999-05-04 Crystallizable jnk complexes Ceased WO1999057253A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000547209A JP2002513562A (en) 1998-05-04 1999-05-04 Crystallizable JNK complex
AU37868/99A AU3786899A (en) 1998-05-04 1999-05-04 Crystallizable jnk complexes
EP99920350A EP1076692A2 (en) 1998-05-04 1999-05-04 Crystallizable jnk complexes
US09/706,128 US7383135B1 (en) 1998-05-04 2000-11-03 Methods of designing inhibitors for JNK kinases
US12/150,328 US8002891B2 (en) 1998-05-04 2008-04-25 Crystallization of C-Jun N-Terminal Kinase 3 (JNK3)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8405698P 1998-05-04 1998-05-04
US60/084,056 1998-05-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/706,128 Continuation US7383135B1 (en) 1998-05-04 2000-11-03 Methods of designing inhibitors for JNK kinases

Publications (2)

Publication Number Publication Date
WO1999057253A2 WO1999057253A2 (en) 1999-11-11
WO1999057253A3 true WO1999057253A3 (en) 1999-12-16

Family

ID=22182612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009824 Ceased WO1999057253A2 (en) 1998-05-04 1999-05-04 Crystallizable jnk complexes

Country Status (4)

Country Link
EP (1) EP1076692A2 (en)
JP (1) JP2002513562A (en)
AU (1) AU3786899A (en)
WO (1) WO1999057253A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US7383135B1 (en) * 1998-05-04 2008-06-03 Vertex Pharmaceuticals Incorporated Methods of designing inhibitors for JNK kinases
ES2230171T3 (en) 1999-11-23 2005-05-01 Smithkline Beecham Corporation 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA COMPOUNDS AS CSBP / P38 QUINASA INHIBITORS.
US6638908B1 (en) 2000-08-09 2003-10-28 Yale University Crystals of the large ribosomal subunit
US6987184B2 (en) 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
AU2003212796A1 (en) * 2002-01-11 2003-07-30 Vertex Pharmaceuticals Incorporated Crystal structures of jnk-inhibitor complexes and binding pockets thereof
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
WO2004099241A1 (en) * 2003-05-09 2004-11-18 Boehringer Ingelheim International Gmbh Hepatitis c virus ns5b polymerase inhibitor binding pocket

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006246A2 (en) * 1995-08-09 1997-02-20 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006246A2 (en) * 1995-08-09 1997-02-20 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIE, X. ET AL: "Crystal structure of JNK3: a kinase implicated in neuronal apoptosis", STRUCTURE, vol. 6, 15 August 1998 (1998-08-15), pages 983 - 991, XP002118848 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Also Published As

Publication number Publication date
AU3786899A (en) 1999-11-23
WO1999057253A2 (en) 1999-11-11
EP1076692A2 (en) 2001-02-21
JP2002513562A (en) 2002-05-14

Similar Documents

Publication Publication Date Title
WO1997006246A3 (en) Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
WO2005105988A3 (en) Crystal structure of human jak3 kinase domain complex and binding pockets thereof
AU2003231232A1 (en) Crystal structure of aurora-2 protein and binding pockets thereof
EP1435957A4 (en) GSK-3 INHIBITORS AND CRYSTALLINE STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES
Van Eldik et al. Calcium-binding proteins and the molecular basis of calcium action
Kremer et al. Structure and thermodynamic stability of lanthanide complexes with amino acids and peptides
CA2353845A1 (en) Integrated data bank combining system
WO2008128050A3 (en) Methods for identification of modulators of carm1 methyl transferase activity
WO2004035604A3 (en) Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof
EP1253598A3 (en) Flash memory capable of changing bank configuration
WO2005056785A3 (en) Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof
WO2003048340A3 (en) Crystal structure of mitogen-activated protein kinase-activated protein kinase 2 and binding pockets thereof
EP0921194A3 (en) TRAILLK-2: a member of the TNF ligand family
WO2001037194A3 (en) Crystallizable compositions comprising a caspase-7
Scott The struggle for the schools.
WO2004023270A3 (en) Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
WO2007146436A3 (en) Crystal structure of polo-like kinase 3 (plk3) and binding pockets thereof
ATE496991T1 (en) CRYSTAL STRUCTURE OF TAK1-TAB1
WO2005028506A3 (en) Crystal structure of fms-like tyrosine kinase
WO2001073108A3 (en) A bacterial two-hybrid system for protein interaction screening
CA2235805A1 (en) Anti-cancer agent
WO2003060102A3 (en) Crystal structures of jnk-inhibitor complexes and binding pockets thereof
WO2003050239A3 (en) Crystals and structures of members of the e. coli coma and yddb protein families (coma)
Pelly How Inuit find their way in the trackless Arctic.
WO1999067375A3 (en) Screening system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 547209

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09706128

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999920350

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999920350

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999920350

Country of ref document: EP